Dr. Marc S. Richards, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,162
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Miami, Lm Miller School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME115086 -
Internal Medicine Physician
FL license ME115086
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boca Raton Regional Hospital Boca Raton, FL
- Bethesda Hospital East Boynton Beach, FL
- Delray Medical Center Delray Beach, FL
- West Boca Medical Center Boca Raton, FL
Medical groups
- Florida Kidney Physicians LLC (169 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,162
- Services billed
- 8,718
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,286 | 626 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,179 | 382 |
| Manual urinalysis test with examination using microscope, automated | 448 | 290 |
| Creatinine level to test for kidney function or muscle injury | 442 | 285 |
| Kidney function blood test panel | 440 | 246 |
| Total protein level, urine | 415 | 277 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 391 | 68 |
| Magnesium level | 388 | 222 |
| Phosphate level | 384 | 219 |
| Dialysis services, per day, less than full month service (20 years or older) | 359 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Farxiga (dapagliflozin propanediol) Other prescribers in Boca Raton, FL | 350 |
| Jardiance (empagliflozin) Other prescribers in Boca Raton, FL | 204 |
| Chlorthalidone Other prescribers in Boca Raton, FL | 198 |
| Irbesartan Other prescribers in Boca Raton, FL | 157 |
| Spironolactone Other prescribers in Boca Raton, FL | 150 |
| Losartan Potassium Other prescribers in Boca Raton, FL | 114 |
| Amlodipine Besylate Other prescribers in Boca Raton, FL | 107 |
| Torsemide Other prescribers in Boca Raton, FL | 83 |
| Bumetanide Other prescribers in Boca Raton, FL | 80 |
| Lisinopril Other prescribers in Boca Raton, FL | 73 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 106 payments worth $31,035 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $9,570 |
|---|---|
| Travere Therapeutics, Inc. | $9,126 |
| Amgen Inc. | $4,761 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,930 |
| Calliditas Therapeutics US Inc. | $2,308 |
| Otsuka America Pharmaceutical, Inc. | $355 |
| Novartis Pharmaceuticals Corporation | $151 |
| Vifor Pharma, Inc. | $147 |
| Speaking at a medical education program | $11,821 |
|---|---|
| Consulting Fee | $9,643 |
| Compensation for services other than consulting (speaking, faculty) | $4,480 |
| Food and Beverage | $2,560 |
| Honoraria | $2,138 |
| Travel and Lodging | $393 |
| Education | $0.39 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $3,360 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Consulting Fee | $3,213 |
| Travere Therapeutics, Inc. Jul 25, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $2,500 |
| Travere Therapeutics, Inc. Aug 20, 2025 | Consulting Fee Filspari · Kidney Disease | $2,500 |
| Travere Therapeutics, Inc. Dec 12, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $2,500 |
| Apellis Pharmaceuticals, Inc. Sep 30, 2025 | Speaking at a medical education program Empaveli · Hematology | $2,111 |
| Apellis Pharmaceuticals, Inc. Oct 21, 2025 | Speaking at a medical education program Empaveli · Hematology | $2,111 |
| Apellis Pharmaceuticals, Inc. Aug 19, 2025 | Speaking at a medical education program Empaveli · Hematology | $2,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 13, 2025 | Consulting Fee | $1,965 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 13, 2025 | Consulting Fee | $1,965 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Dec 12, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $2,500 |
| Apellis Pharmaceuticals, Inc. Oct 21, 2025 | Speaking at a medical education program Empaveli · Hematology | $2,111 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 13, 2025 | Consulting Fee | $1,965 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Oct 13, 2025 | Consulting Fee | $1,965 |
| Travere Therapeutics, Inc. Oct 13, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
| Travere Therapeutics, Inc. Oct 8, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $600 |
| Apellis Pharmaceuticals, Inc. Sep 30, 2025 | Speaking at a medical education program Empaveli · Hematology | $2,111 |
| Calliditas Therapeutics US Inc. Sep 10, 2025 | Honoraria TARPEYO · NEPHROLOGY | $950 |
| Travere Therapeutics, Inc. Aug 21, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Fort Myers, FL · in-kind | $217 |
| Travere Therapeutics, Inc. Aug 20, 2025 | Consulting Fee Filspari · Kidney Disease | $2,500 |
| Apellis Pharmaceuticals, Inc. Aug 19, 2025 | Speaking at a medical education program Empaveli · Hematology | $2,000 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Consulting Fee | $3,213 |
| Travere Therapeutics, Inc. Jul 31, 2025 | Travel and Lodging Filspari · Kidney Disease · travel to Fort Myers, FL · in-kind | $176 |
| Travere Therapeutics, Inc. Jul 25, 2025 | Speaking at a medical education program Filspari · Kidney Disease | $2,500 |
| Amgen Inc. Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $3,360 |
| Calliditas Therapeutics US Inc. Apr 30, 2025 | Honoraria TARPEYO · NEPHROLOGY | $1,188 |
| Amgen Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $1,120 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $179,060 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Amgen Inc. - Nef-403
Calliditas Therapeutics US Inc. - An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.